Promising data in myasthenia gravis, plus a pledge to compete on price, means that Ra Pharmaceuticals’ zilucoplan could soon give Alexion a headache – and others are…
Pfizer and Merck & Co take increases, making it easier for others to follow. But shifts in congressional power means pricing will remain a minefield.
For biotechs nearing regulatory approval the key is to sell before launch. For buyers, playing the waiting game is a better strategy.
The amyloid beta hypothesis persists in spite of repeated failure as biopharma refines targets and mechanisms of action.
Abbvie's latest move to shore up Humira sales against a biosimilar onslaught involves politically sensitive price hikes.
Novartis's $4m price target for AVXS-101 fuels concerns that too many new gene therapies could overburden payers without a hard look at how they are financed.
Roche is stepping up the defence of its eye franchise, but the real test will come with pivotal readouts for its new contender versus Regeneron’s Eylea.
Krystal Biotech shares have surged 53% so far this week on gene therapy data in two patients, but rivals are waiting in the wings.
Promising mid-stage data with Merck KGaA’s evobrutinib in multiple sclerosis could help the German group carve out a niche for its BTK inhibitor – unless bigger players…